Phase 2 N=13 Acetyl-L-Carnitine in the Treatment of Septic Shock
Septic Shock
Primary: Mean Arterial Blood Pressure — 60; 60 mm Hg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=80 Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms
Major Depressive Disorder · Dysthymia · Depression Not Otherwise Specified
Primary: Sheehan-Suicidality Tracking Scale (S-STS) — 4.8; 5.0 Scores on a Scale (S-STSS)
Phase 2 N=18 Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases
Metastatic Cancer · Pain · Prostate Cancer
Primary: 8-week Freedom-From-Progression (FFP) — 2; 15 participants
Phase 2 N=302 Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients
Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 12 — 0.18; 0.04; -0.24; -0.28 percent — p=0.3271
Phase 2 N=121 A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
Non-Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 6.05; 4.50 months
Phase 2 N=30 Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Primary: Number of Participants With Progression Free Survival at 2 Years — 13 Participants
Phase 2 N=5 Sirolimus to Treat Diabetic Macular Edema
Diabetic Retinopathy
Primary: Change in Visual Acuity From Baseline to 6 Months — 7; 0 ETDRS letters
Phase 2 N=19 Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 2) — 6 Participants
Phase 2 N=101 Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma
Cancer · Melanoma
Primary: Progression Free Survival (PFS) — 148; 82 days — p=0.068
Phase 2 N=22 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
Anaplastic Large Cell Lymphoma · Recurrent Adult Hodgkin Lymphoma · Recurrent Mantle Cell Lymphoma
Primary: Number of Patients With Response — 0; 2 participants
Phase 2 N=50 ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer
Breast Cancer
Primary: Proportion of Patients With Confirmed Responses — 25; 50 participants
Phase 2 N=217 Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome
Restless Legs Syndrome
Primary: Mean Css, Max and Css, Min — 3.86; 7.14; 11.4; 14.0 nanograms per milliliter (ng/ml)
Phase 2 N=124 Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndrome · Chronic Myelomonocytic Leukemia
Primary: Participant Responses — 4; 47; 4; 6 Participants
Phase 2 N=531 Sanofi Pasteur, TIV + H1N1, Pediatric Population
Influenza
Primary: Number of Participants Age 6 Months to Less Than 36 Months With 4-fold or Greater Hemagglutination Inhibition Assay (HAI) Antibody Titer Increases Against the Influenza…
Phase 2 N=25 Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy
Epilepsy
Primary: Maximum Concentration at Steady State (Cmax) of Keppra XR Normalized by Dose and by Body Weight and Dose During up to 7 Days of Administration — 17.3; 14.9; 1.27; 1.24…